CD34 and myocardial ischemia: Recently, Das et al. reported a promising method of regenerative therapy using transiently overexpressed angiogenic genes VEGF and PDGF in ex vivo expanded human umbilical cord blood-derived CD133+/CD34+ progenitor cells while using a bicistronic vector, in which both VEGF-A164 and PDGF-BB genes under CMV promoter, to augment stem cell effect for treatment of myocardial ischemia induced in the rat model [35].